2025 Q4 -tulosraportti
Vain PDF
12 päivää sitten
Tarjoustasot
First North Sweden
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 816 | - | - | ||
| 734 | - | - | ||
| 175 | - | - | ||
| 131 | - | - | ||
| 24 431 | - | - |
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 895 557 | 895 557 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 895 557 | 895 557 | 0 | 0 |
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 29.4. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 27.2. | ||
2025 Q3 -tulosraportti 27.11.2025 | ||
2025 Q2 -tulosraportti 27.8.2025 | ||
2025 Q1 -tulosraportti 22.5.2025 | ||
2024 Q4 -tulosraportti 25.2.2025 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·10 t sittenUnfortunately, we will soon see 4:-
1 t sitten1 t sittenA penny stock rating of literal 2-3SEK range would be the death of any and all investor interest in this for a long while.
·6.3.Here is a possible scenario for Sereno Scientific in the coming years. This is a hypothetical investment scenario based on how small biotech companies typically develop. Scenario: Sereno Scientific succeeds with the treatment 1️⃣ 2026 – Strong clinical data Sereno is developing the drug CS1 for the treatment of Pulmonary Arterial Hypertension (PAH). If new studies show: • improved blood pressure in the lungs • improved quality of life for patients • few serious side effects it could generate significant market interest. Possible reaction: • investors buy the stock • the share price could increase 2–4× on good results. 2️⃣ 2027 – Partnership with a larger pharmaceutical company If the study results are strong, a larger pharmaceutical company could become a partner. Typical structure: • upfront payment (e.g., $10–30 million) • milestone payments • royalty on future sales This could provide: • more funding • faster development of the medicine. Possible share price reaction: • 4–8× from current levels. 3️⃣ 2028–2030 – Phase 3 and market approval If the treatment succeeds in later studies and is approved: • the medicine could be used globally • the market for PAH medicines is several billion dollars. In such a scenario, the company's value could become several billion kroner. Possible long-term upside: • 10–20× from today's share price.·6.3.Some reflections. Scenario 1: a doubling of market cap from the current level would land approximately where the peak was in May last year. Not very impressive. Scenario 3: to be able to take the molecule through phase 3 requires significant additional financing and thus dilution of the current share price. However - with new signals from the FDA that one (instead of two) well-designed phase 3 study might be sufficient for market approval (https://www.biospace.com/fda/its-official-fda-will-now-default-to-one-clinical-trial-for-drug-applications), it could become more attractive for Cereno to carry out the entire approval process themselves. To do that, however, more capital and a different capacity are required. It would be interesting to hear how they themselves think about it.
·1 päivä sittenI have followed other small Medtechs reach approximately this point where C is today, and subsequently, it becomes a much larger undertaking for those involved, at which point the individuals in the group can start to lose their drive. More time is then spent on financing, and the research itself suffers. Therefore, interest in collaboration with larger Medtechs should be appealing, which not infrequently leads to internal issues. I hope it finds a good balance and that the substance reaches those in need, as I believe it is a good agent.- 5.3.5.3.I have a prediction: If the CU/EAP readout doesn‘t show positive efficacy readouts this is going to hit the floor. The valuation of Cereno rose sharply after P1 concluded for CS01 and we saw some more positive trending after CS014 readouts as well. However the sharp rises to 10SEK were shown to be unsubstantiated in the long term due to various factors such as no BP/Licensing deal coming out, financing hurdles (these days resolved) and lack of efficacy data in favor of a large readout in safety and tolerability profiles. We have now for months and months seen the valuation tank back down setting lower lows as the market has come to terms with the above circumstances and I fear that one less than stellar readout will jeopardize the stock valuation all together. I have trust in Cereno‘s leadership and long term vision, but the echo chamber atmosphere of the discord combined with the realities of current market valuation and trend is to say the least: worrying. It‘s never a good sign when massive hype and denial of discussing downsides and opposing views exist in the same space - especially when combined with a market valuation that has seen a significant fall off in the past 6 months with no signs of getting better. So, I hope we see a very - very positive CU/EAP readout in terms of efficacy, or I fear we‘re in for another slope downwards.·1 päivä sittenFinally another one who dares to look outside the box! Just staring and listening to the most entrenched in a matter becomes a bit like cult-like behavior. Defending others' and my own thinking to the absurd is unfortunately part of human weakness. Then it's good to have people like GrazieMille99 who ventilate circumstances from other angles. Good 👍🏼 and strong and valuable.
- ·3.3.There is a nervousness in the market that is pulling down the stock. I am holding long-term in an exciting stock that has untold possibilities to go very high. I'll be on board when the train leaves. I won't be left behind on the platform like many will be when they are selling out now.
·4.3.Technical analysis says the floor is now 4.90kr. Sounds low but BV is still far over a billion. Is it worth a billion at present is the big question?·5.3. · MuokattuThe valuation is a great advantage for Elicera. In the end, it's about succeeding. Currently, I think E.'s studies show better results. It's about reaching the finish line. Both can cross the finish line. Summarized. R/R clearly better for E. currently. - ·3.3.No one can say I wasn't right...And guess what ?? Further down we shall so you know...
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
Vain PDF
12 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·10 t sittenUnfortunately, we will soon see 4:-1 t sitten1 t sittenA penny stock rating of literal 2-3SEK range would be the death of any and all investor interest in this for a long while.
- ·6.3.Here is a possible scenario for Sereno Scientific in the coming years. This is a hypothetical investment scenario based on how small biotech companies typically develop. Scenario: Sereno Scientific succeeds with the treatment 1️⃣ 2026 – Strong clinical data Sereno is developing the drug CS1 for the treatment of Pulmonary Arterial Hypertension (PAH). If new studies show: • improved blood pressure in the lungs • improved quality of life for patients • few serious side effects it could generate significant market interest. Possible reaction: • investors buy the stock • the share price could increase 2–4× on good results. 2️⃣ 2027 – Partnership with a larger pharmaceutical company If the study results are strong, a larger pharmaceutical company could become a partner. Typical structure: • upfront payment (e.g., $10–30 million) • milestone payments • royalty on future sales This could provide: • more funding • faster development of the medicine. Possible share price reaction: • 4–8× from current levels. 3️⃣ 2028–2030 – Phase 3 and market approval If the treatment succeeds in later studies and is approved: • the medicine could be used globally • the market for PAH medicines is several billion dollars. In such a scenario, the company's value could become several billion kroner. Possible long-term upside: • 10–20× from today's share price.·6.3.Some reflections. Scenario 1: a doubling of market cap from the current level would land approximately where the peak was in May last year. Not very impressive. Scenario 3: to be able to take the molecule through phase 3 requires significant additional financing and thus dilution of the current share price. However - with new signals from the FDA that one (instead of two) well-designed phase 3 study might be sufficient for market approval (https://www.biospace.com/fda/its-official-fda-will-now-default-to-one-clinical-trial-for-drug-applications), it could become more attractive for Cereno to carry out the entire approval process themselves. To do that, however, more capital and a different capacity are required. It would be interesting to hear how they themselves think about it.·1 päivä sittenI have followed other small Medtechs reach approximately this point where C is today, and subsequently, it becomes a much larger undertaking for those involved, at which point the individuals in the group can start to lose their drive. More time is then spent on financing, and the research itself suffers. Therefore, interest in collaboration with larger Medtechs should be appealing, which not infrequently leads to internal issues. I hope it finds a good balance and that the substance reaches those in need, as I believe it is a good agent.
- 5.3.5.3.I have a prediction: If the CU/EAP readout doesn‘t show positive efficacy readouts this is going to hit the floor. The valuation of Cereno rose sharply after P1 concluded for CS01 and we saw some more positive trending after CS014 readouts as well. However the sharp rises to 10SEK were shown to be unsubstantiated in the long term due to various factors such as no BP/Licensing deal coming out, financing hurdles (these days resolved) and lack of efficacy data in favor of a large readout in safety and tolerability profiles. We have now for months and months seen the valuation tank back down setting lower lows as the market has come to terms with the above circumstances and I fear that one less than stellar readout will jeopardize the stock valuation all together. I have trust in Cereno‘s leadership and long term vision, but the echo chamber atmosphere of the discord combined with the realities of current market valuation and trend is to say the least: worrying. It‘s never a good sign when massive hype and denial of discussing downsides and opposing views exist in the same space - especially when combined with a market valuation that has seen a significant fall off in the past 6 months with no signs of getting better. So, I hope we see a very - very positive CU/EAP readout in terms of efficacy, or I fear we‘re in for another slope downwards.·1 päivä sittenFinally another one who dares to look outside the box! Just staring and listening to the most entrenched in a matter becomes a bit like cult-like behavior. Defending others' and my own thinking to the absurd is unfortunately part of human weakness. Then it's good to have people like GrazieMille99 who ventilate circumstances from other angles. Good 👍🏼 and strong and valuable.
- ·3.3.There is a nervousness in the market that is pulling down the stock. I am holding long-term in an exciting stock that has untold possibilities to go very high. I'll be on board when the train leaves. I won't be left behind on the platform like many will be when they are selling out now.·4.3.Technical analysis says the floor is now 4.90kr. Sounds low but BV is still far over a billion. Is it worth a billion at present is the big question?·5.3. · MuokattuThe valuation is a great advantage for Elicera. In the end, it's about succeeding. Currently, I think E.'s studies show better results. It's about reaching the finish line. Both can cross the finish line. Summarized. R/R clearly better for E. currently.
- ·3.3.No one can say I wasn't right...And guess what ?? Further down we shall so you know...
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
First North Sweden
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 816 | - | - | ||
| 734 | - | - | ||
| 175 | - | - | ||
| 131 | - | - | ||
| 24 431 | - | - |
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 895 557 | 895 557 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 895 557 | 895 557 | 0 | 0 |
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 29.4. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 27.2. | ||
2025 Q3 -tulosraportti 27.11.2025 | ||
2025 Q2 -tulosraportti 27.8.2025 | ||
2025 Q1 -tulosraportti 22.5.2025 | ||
2024 Q4 -tulosraportti 25.2.2025 |
2025 Q4 -tulosraportti
Vain PDF
12 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 29.4. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 27.2. | ||
2025 Q3 -tulosraportti 27.11.2025 | ||
2025 Q2 -tulosraportti 27.8.2025 | ||
2025 Q1 -tulosraportti 22.5.2025 | ||
2024 Q4 -tulosraportti 25.2.2025 |
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·10 t sittenUnfortunately, we will soon see 4:-1 t sitten1 t sittenA penny stock rating of literal 2-3SEK range would be the death of any and all investor interest in this for a long while.
- ·6.3.Here is a possible scenario for Sereno Scientific in the coming years. This is a hypothetical investment scenario based on how small biotech companies typically develop. Scenario: Sereno Scientific succeeds with the treatment 1️⃣ 2026 – Strong clinical data Sereno is developing the drug CS1 for the treatment of Pulmonary Arterial Hypertension (PAH). If new studies show: • improved blood pressure in the lungs • improved quality of life for patients • few serious side effects it could generate significant market interest. Possible reaction: • investors buy the stock • the share price could increase 2–4× on good results. 2️⃣ 2027 – Partnership with a larger pharmaceutical company If the study results are strong, a larger pharmaceutical company could become a partner. Typical structure: • upfront payment (e.g., $10–30 million) • milestone payments • royalty on future sales This could provide: • more funding • faster development of the medicine. Possible share price reaction: • 4–8× from current levels. 3️⃣ 2028–2030 – Phase 3 and market approval If the treatment succeeds in later studies and is approved: • the medicine could be used globally • the market for PAH medicines is several billion dollars. In such a scenario, the company's value could become several billion kroner. Possible long-term upside: • 10–20× from today's share price.·6.3.Some reflections. Scenario 1: a doubling of market cap from the current level would land approximately where the peak was in May last year. Not very impressive. Scenario 3: to be able to take the molecule through phase 3 requires significant additional financing and thus dilution of the current share price. However - with new signals from the FDA that one (instead of two) well-designed phase 3 study might be sufficient for market approval (https://www.biospace.com/fda/its-official-fda-will-now-default-to-one-clinical-trial-for-drug-applications), it could become more attractive for Cereno to carry out the entire approval process themselves. To do that, however, more capital and a different capacity are required. It would be interesting to hear how they themselves think about it.·1 päivä sittenI have followed other small Medtechs reach approximately this point where C is today, and subsequently, it becomes a much larger undertaking for those involved, at which point the individuals in the group can start to lose their drive. More time is then spent on financing, and the research itself suffers. Therefore, interest in collaboration with larger Medtechs should be appealing, which not infrequently leads to internal issues. I hope it finds a good balance and that the substance reaches those in need, as I believe it is a good agent.
- 5.3.5.3.I have a prediction: If the CU/EAP readout doesn‘t show positive efficacy readouts this is going to hit the floor. The valuation of Cereno rose sharply after P1 concluded for CS01 and we saw some more positive trending after CS014 readouts as well. However the sharp rises to 10SEK were shown to be unsubstantiated in the long term due to various factors such as no BP/Licensing deal coming out, financing hurdles (these days resolved) and lack of efficacy data in favor of a large readout in safety and tolerability profiles. We have now for months and months seen the valuation tank back down setting lower lows as the market has come to terms with the above circumstances and I fear that one less than stellar readout will jeopardize the stock valuation all together. I have trust in Cereno‘s leadership and long term vision, but the echo chamber atmosphere of the discord combined with the realities of current market valuation and trend is to say the least: worrying. It‘s never a good sign when massive hype and denial of discussing downsides and opposing views exist in the same space - especially when combined with a market valuation that has seen a significant fall off in the past 6 months with no signs of getting better. So, I hope we see a very - very positive CU/EAP readout in terms of efficacy, or I fear we‘re in for another slope downwards.·1 päivä sittenFinally another one who dares to look outside the box! Just staring and listening to the most entrenched in a matter becomes a bit like cult-like behavior. Defending others' and my own thinking to the absurd is unfortunately part of human weakness. Then it's good to have people like GrazieMille99 who ventilate circumstances from other angles. Good 👍🏼 and strong and valuable.
- ·3.3.There is a nervousness in the market that is pulling down the stock. I am holding long-term in an exciting stock that has untold possibilities to go very high. I'll be on board when the train leaves. I won't be left behind on the platform like many will be when they are selling out now.·4.3.Technical analysis says the floor is now 4.90kr. Sounds low but BV is still far over a billion. Is it worth a billion at present is the big question?·5.3. · MuokattuThe valuation is a great advantage for Elicera. In the end, it's about succeeding. Currently, I think E.'s studies show better results. It's about reaching the finish line. Both can cross the finish line. Summarized. R/R clearly better for E. currently.
- ·3.3.No one can say I wasn't right...And guess what ?? Further down we shall so you know...
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
First North Sweden
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 816 | - | - | ||
| 734 | - | - | ||
| 175 | - | - | ||
| 131 | - | - | ||
| 24 431 | - | - |
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 895 557 | 895 557 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 895 557 | 895 557 | 0 | 0 |